| First Author | Yoo SH | Year | 2013 |
| Journal | Biochem Biophys Res Commun | Volume | 436 |
| Issue | 3 | Pages | 366-71 |
| PubMed ID | 23727576 | Mgi Jnum | J:204426 |
| Mgi Id | MGI:5532477 | Doi | 10.1016/j.bbrc.2013.05.073 |
| Citation | Yoo SH, et al. (2013) Activation of PPARalpha by Wy-14643 ameliorates systemic lipopolysaccharide-induced acute lung injury. Biochem Biophys Res Commun 436(3):366-71 |
| abstractText | Acute lung injury (ALI) is a major cause of mortality and morbidity worldwide. The activation of peroxisome proliferator-activated receptor-alpha (PPARalpha) by its ligands, which include Wy-14643, has been implicated as a potential anti-inflammatory therapy. To address the beneficial efficacy of Wy-14643 for ALI along with systemic inflammation, the in vivo role of PPARalpha activation was investigated in a mouse model of lipopolysaccharide (LPS)-induced ALI. Using age-matched Ppara-null and wild-type mice, we demonstrate that the activation of PPARalpha by Wy-14643 attenuated LPS-mediated ALI. This was evidenced histologically by the significant alleviation of inflammatory manifestations and apoptosis observed in the lung tissues of wild-type mice, but not in the corresponding Ppara-null mice. This protective effect probably resulted from the inhibition of LPS-induced increases in pro-inflammatory cytokines and nitroxidative stress levels. These results suggest that the pharmacological activation of PPARalpha might have a therapeutic effect on LPS-induced ALI. |
